Bidness Etc
September 10, 2016
The future of intelligent curated financial data.

Amgen, Inc: PCSK9 Litigation May Lead To $8 Upside

Amgen, Inc. ( NASDAQ:AMGN ) is currently in a patent dispute against development partners Regeneron Pharmaceuticals Inc ( NASDAQ:REGN ) and Sanofi SA (ADR) (NYSE:SNY) over its PCSK9 inhibitor Praluent. The Food and Drug Administration (FDA) approved Praluent ar... Read More http://hvst.co/2csTSjr 

More from Bidness Etc
The most important insight of the day
Get the Harvest Daily Digest newsletter.